Ross G. Clark
57Patents
19h-index
43Co-inventors
84Inventor score
Filing activity: Jun 7, 1990 → Mar 12, 2012
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5849535A | Human growth hormone variants | Emerging Cross-Sectional Technologies | 153 | Expired |
| US5597797A | Method for treatment or prevention of obesity | Human Necessities | 126 | Expired |
| US6057292A | Method for inhibiting growth hormone action | Emerging Cross-Sectional Technologies | 101 | Expired |
| US5374620A | Growth-promoting composition and its use | Emerging Cross-Sectional Technologies | 88 | Expired |
| US5126324A | Method of enhancing growth in patients using combination therapy | Human Necessities | 82 | Expired |
| US5187151A | Use of binding protein with IGF-I as an anabolic growth promoting agent | Human Necessities | 78 | Expired |
| US5935924A | Treatment of congestive heart failure | Human Necessities | 59 | Expired |
| US5783556A | Formulated insulin-containing composition | Human Necessities | 52 | Expired |
| US5273961A | Method of prophylaxis of acute renal failure | Human Necessities | 50 | Expired |
| US6004931A | Method for inhibiting growth hormone action | Emerging Cross-Sectional Technologies | 46 | Expired |
| US5202119A | Method of stimulating immune response | Human Necessities | 45 | Expired |
| US7258864B2 | Methods for treatment of insulin-like growth factor-1 (IGF-1) deficiency | Physics | 34 | Expired |
| US5593844A | Ligand-mediated immunofunctional hormone binding protein assay method | Physics | 34 | Expired |
| US5210017A | Ligand-mediated immunofunctional hormone binding protein assay method | Emerging Cross-Sectional Technologies | 32 | Expired |
| US7517530B2 | Methods for treatment of insulin-like growth factor-1 (IGF-1) deficiency comprising administration of IGF-1 and growth hormone | Physics | 31 | Active |
| US5614487A | Sustained release pharmaceutical composition | Human Necessities | 31 | Expired |
| US6136563A | Human growth hormone variants comprising amino acid substitutions | Emerging Cross-Sectional Technologies | 29 | Expired |
| US5798337A | Low molecular weight peptidomimetic growth hormone secretagogues | Human Necessities | 27 | Expired |
| US5681814A | Formulated IGF-I Composition | Human Necessities | 19 | Expired |
| US6750321B1 | Insulin-like growth factor agonist molecules | Emerging Cross-Sectional Technologies | 17 | Expired |
| US5661122A | Treatment of congestive heart failure | Human Necessities | 16 | Expired |
| US5741776A | Method of administration of IGF-I | Human Necessities | 14 | Expired |
| US6121416A | Insulin-like growth factor agonist molecules | Emerging Cross-Sectional Technologies | 13 | Expired |
| US5565428A | Method of administration of IGF-I | Human Necessities | 12 | Expired |
| US6251865A | Insulin-like growth factor agonist molecules | Emerging Cross-Sectional Technologies | 12 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.